Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19343371 | THERAPEUTIC COMPOSITIONS FOR TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS | September 2025 | February 2026 | Allow | 5 | 1 | 0 | No | No |
| 19206964 | COMPOSITION AND METHOD FOR TREATING HEARING LOSS | May 2025 | September 2025 | Allow | 5 | 1 | 0 | Yes | No |
| 18799983 | COMPOSITION AND METHOD FOR TREATING HEARING LOSS | August 2024 | April 2025 | Allow | 8 | 1 | 1 | Yes | No |
| 18777570 | METHODS FOR PREPARING PRODUCTS FOR TREATING SCALD INFECTION CAUSED BY PSEUDOMONAS AERUGINOSA | July 2024 | January 2025 | Allow | 6 | 1 | 0 | Yes | No |
| 18760549 | COMPOSITIONS AND METHODS FOR SUNLESS TANNING | July 2024 | January 2025 | Allow | 6 | 2 | 0 | Yes | No |
| 18665804 | BENDAMUSTINE PHARMACEUTICAL COMPOSITIONS | May 2024 | February 2026 | Allow | 21 | 0 | 0 | No | No |
| 18660021 | NEW MODIFIED RELEASE ORAL CONTRACEPTIVE COMPOSITION | May 2024 | May 2025 | Allow | 12 | 2 | 0 | Yes | No |
| 18655687 | COMPOSITIONS AND DOSAGE FORMS FOR ORAL DELIVERY | May 2024 | June 2025 | Allow | 13 | 1 | 0 | Yes | No |
| 18620329 | IMPLANTABLE DEPOTS FOR THE CONTROLLED RELEASE OF THERAPEUTIC AGENTS | March 2024 | February 2025 | Allow | 11 | 1 | 0 | Yes | No |
| 18592160 | SOLID SELF-EMULSIFYING PHARMACEUTICAL COMPOSITIONS | February 2024 | March 2025 | Abandon | 13 | 1 | 0 | No | No |
| 18681466 | SMALL EXTRACELLULAR VESICLES EXPRESSING A DOMINANT NEGATIVE AMPK ALPHA 1 MUTANT FOR USE IN THE TREATMENT OF OBESITY | February 2024 | November 2025 | Allow | 22 | 0 | 0 | Yes | No |
| 18425556 | Local delivery of antineoplastic particles in combination with systemic delivery of immunotherapeutic agents for the treatment of cancer | January 2024 | April 2025 | Allow | 14 | 2 | 0 | Yes | No |
| 18576171 | USE OF A VEGETABLE EXTRACT FROM SALVIA HAENKEI AS AN ACTIVE AGENT IN THE TREATMENT OF HEART DISEASES | January 2024 | March 2025 | Allow | 14 | 2 | 0 | No | No |
| 18399546 | Methods for the preparation of biologically active compounds in nanoparticulate form | December 2023 | August 2025 | Abandon | 20 | 1 | 0 | No | No |
| 18543854 | CROSS LINKED SILK-HYALURONIC ACID COMPOSITION | December 2023 | March 2025 | Abandon | 15 | 1 | 0 | No | No |
| 18564822 | COMPOSITIONS AND METHODS FOR INHIBITING AN INFLAMMATORY RESPONSE AND TREATING INFLAMMATORY DISEASES | November 2023 | October 2025 | Allow | 23 | 0 | 0 | Yes | No |
| 18562492 | COMPOSITION COMPRISING AN ESTER OF ALPHA-TOCOPHEROL FOR REDUCING THE RISK OF PRETERM BIRTH | November 2023 | July 2025 | Allow | 19 | 4 | 0 | Yes | No |
| 18500489 | COMPOSITION OF MATTER COMPRISING LIPOSOMES EMBEDDED IN A POLYMERIC MATRIX AND METHODS OF USING SAME | November 2023 | December 2025 | Allow | 26 | 1 | 0 | No | No |
| 18484519 | HAIR PROTECTION AND RESTRUCTURING METHOD AND THE RELATED COMPOSITIONS | October 2023 | November 2025 | Allow | 26 | 0 | 0 | No | No |
| 18470768 | METHOD FOR PREPARING A HAEMOSTATIC COMPOSITION | September 2023 | October 2025 | Allow | 25 | 3 | 0 | No | No |
| 18467953 | METHODS OF TREATING ENDOMETRIAL CANCER USING HEMP EXTRACT | September 2023 | November 2024 | Allow | 14 | 1 | 0 | Yes | No |
| 18467093 | TREATMENT AND PREVENTION OF INJURY DUE TO RADIATION EXPOSURE | September 2023 | July 2025 | Abandon | 23 | 2 | 0 | No | No |
| 18463691 | ENZYMATICALLY CROSSLINKED COMPOSITIONS | September 2023 | October 2025 | Abandon | 25 | 2 | 1 | Yes | No |
| 18462346 | HERNIA REPAIR, BREAST RECONSTRUCTION AND SLING DEVICES CONTAINING POLY(BUTYLENE SUCCINATE) AND COPOLYMERS THEREOF | September 2023 | November 2025 | Allow | 26 | 4 | 0 | Yes | No |
| 18240488 | ANTIMICROBIAL BANDAGE | August 2023 | December 2024 | Allow | 16 | 2 | 0 | Yes | No |
| 18365416 | ELECTROSPUN STRUCTURES HAVING A PHARMACEUTICAL AND METHODS OF MAKING AND USING THE SAME | August 2023 | October 2025 | Abandon | 26 | 2 | 1 | No | No |
| 18351711 | Treatment of Epithelial Cysts by Intracystic Injection of Antineoplastic Particles | July 2023 | August 2024 | Allow | 13 | 1 | 0 | Yes | No |
| 18259175 | METHOD OF OBTAINING A PHARMACEUTICAL AGENT USED FOR INHIBITING THE PROLIFERATION OF TUMOR CELLS | June 2023 | January 2026 | Allow | 30 | 1 | 0 | Yes | No |
| 18257539 | NANOSYSTEMS BASED ON NANOCOMPOSITES AND NATURAL EXTRACTS | June 2023 | October 2025 | Allow | 28 | 2 | 1 | Yes | No |
| 18265903 | ANTI-OBESITY POTENTIAL OF BISDEMETHOXYCURCUMIN COMPOSITIONS | June 2023 | February 2025 | Abandon | 20 | 1 | 0 | No | No |
| 18256021 | FORMULATIONS FOR NON-PARENTERAL ADMINISTRATION OF EXOSOMES | June 2023 | January 2026 | Abandon | 31 | 1 | 0 | No | No |
| 18200980 | BENDAMUSTINE PHARMACEUTICAL COMPOSITIONS | May 2023 | July 2024 | Abandon | 14 | 1 | 0 | No | No |
| 18319948 | TOPICAL TREATMENT FOR ANIMALS | May 2023 | August 2024 | Abandon | 15 | 0 | 1 | No | No |
| 18305051 | METHODS FOR FABRICATING ISOLATED MICRO- OR NANO-STRUCTURES USING SOFT OR IMPRINT LITHOGRAPHY | April 2023 | May 2024 | Abandon | 13 | 1 | 0 | No | No |
| 18030832 | NICOTINAMIDE-ENCAPSULATING MICELLES, AND PREGNANCY-INDUCED HYPERTENSION SYNDROME THERAPY COMPOSITION CONTAINING NICOTINAMIDE-ENCAPSULATING MICELLES | April 2023 | December 2025 | Abandon | 32 | 1 | 0 | No | No |
| 18130484 | MALLEABLE, CRYOPRESERVED OSTEOGENIC COMPOSITIONS WITH VIABLE CELLS | April 2023 | August 2025 | Abandon | 28 | 4 | 1 | No | No |
| 18295670 | PHARMACEUTICAL FORMULATION | April 2023 | May 2024 | Allow | 13 | 1 | 0 | Yes | No |
| 18023233 | INHIBITORS OF NO PRODUCTION | February 2023 | February 2026 | Abandon | 35 | 1 | 0 | No | No |
| 18022343 | PRODUCTS AND METHODS FOR INCREASING NITRIC OXIDE PRODUCTION AND MANAGING OXIDATIVE STRESS | February 2023 | January 2026 | Abandon | 35 | 1 | 0 | No | No |
| 18041449 | GASTRO-RESISTANT HIGH-STRENGTH FORMULATION CONTAINING POSACONAZOLE | February 2023 | March 2026 | Allow | 37 | 1 | 0 | No | No |
| 18021165 | NEW MODIFIED RELEASE ORAL CONTRACEPTIVE COMPOSITION | February 2023 | May 2025 | Allow | 27 | 2 | 0 | Yes | No |
| 18006889 | ACCELERATING REPAIR OF MUCOSAL INJURY USING GOLD(III) COMPOUNDS | January 2023 | September 2025 | Allow | 31 | 1 | 0 | Yes | No |
| 18154419 | Local delivery of antineoplastic particles in combination with systemic delivery of immunotherapeutic agents for the treatment of cancer | January 2023 | November 2023 | Allow | 10 | 1 | 0 | Yes | No |
| 17789662 | BENZOPYRAZOLE COMPOUND | December 2022 | October 2025 | Allow | 39 | 1 | 0 | Yes | No |
| 18082275 | Compositions for the Treatment of Dry Eye and Methods of Use Thereof | December 2022 | February 2025 | Abandon | 26 | 2 | 1 | Yes | No |
| 18077390 | METHOD OF TREATING CANCER | December 2022 | November 2025 | Abandon | 36 | 1 | 0 | No | No |
| 18061309 | PYRAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | December 2022 | January 2026 | Allow | 37 | 1 | 0 | No | No |
| 18070021 | Self-Neutralizing Amino Acid Based Cationic Compositions | November 2022 | November 2024 | Allow | 23 | 3 | 0 | Yes | No |
| 18059270 | THERAPEUTIC COMPOUNDS, FORMULATIONS, AND USES THEREOF | November 2022 | April 2024 | Allow | 16 | 1 | 0 | No | No |
| 17999233 | Selenium-Based Compositions and Therapeutic Methods | November 2022 | November 2025 | Abandon | 36 | 1 | 0 | No | No |
| 17984001 | COMPOSITIONS AND METHODS OF ADMINISTERING BACLOFEN | November 2022 | February 2024 | Allow | 15 | 1 | 0 | Yes | No |
| 17997134 | SELF-TANNING COMPOSITIONS CONTAINING AN AROMATIC SULFONATE AND METHODS THEREOF | October 2022 | November 2025 | Allow | 36 | 1 | 0 | No | No |
| 18050021 | METHODS OF TREATING ENDOMETRIAL CANCER USING HEMP EXTRACT | October 2022 | September 2023 | Allow | 10 | 1 | 1 | Yes | No |
| 17920850 | IL4I1 INHIBITORS AND METHODS OF USE | October 2022 | July 2025 | Allow | 33 | 1 | 0 | No | No |
| 17966916 | Composition and method of treatment of elevated ApoE gene expression related health issues | October 2022 | February 2023 | Allow | 4 | 1 | 1 | Yes | No |
| 17966901 | Composition and method of treatment of health issues related to estrogen metabolism with elevated risk factors in females | October 2022 | February 2023 | Allow | 4 | 1 | 1 | Yes | No |
| 18046002 | Treatment of Epithelial Cysts by Intracystic Injection of Antineoplastic Particles | October 2022 | June 2023 | Allow | 8 | 1 | 0 | No | No |
| 17962753 | EDIBLE COMPOSITION FOR ALLEVIATING VISUAL FATIGUE | October 2022 | July 2025 | Allow | 33 | 1 | 0 | No | No |
| 17917774 | LOW ENDOTOXIN GELATIN-(METH)ACRYLOYL | October 2022 | April 2025 | Allow | 30 | 1 | 1 | Yes | No |
| 17958322 | Composition and manufacturing processes of a toxicity free botanical drug for relief from breathing difficulties | October 2022 | February 2026 | Abandon | 41 | 2 | 0 | No | No |
| 17907262 | COMPOSITIONS FOR TREATMENT OF PSORIASIS OF THE SCALP | September 2022 | October 2025 | Abandon | 37 | 1 | 0 | No | No |
| 17914237 | NOVEL CERIUM OXIDE NANOCOMPOSITE AND USE THEREOF | September 2022 | July 2025 | Allow | 34 | 1 | 0 | No | No |
| 17948611 | MANUFACTURE OF PEANUT FORMULATIONS FOR ORAL DESENSITIZATION | September 2022 | November 2025 | Abandon | 38 | 1 | 0 | No | No |
| 17942396 | METHOD OF IDENTIFYING AND TREATING PREMATURE INFANTS AT RISK FOR BPD | September 2022 | January 2024 | Allow | 17 | 1 | 0 | Yes | No |
| 17910868 | PARTICLE SIZE CONTROL | September 2022 | November 2025 | Abandon | 38 | 1 | 0 | No | No |
| 17905821 | METHOD FOR PREPARING POLYDOPAMINE NANOMOTOR USING UREASE, AND USE OF SAME | September 2022 | January 2026 | Allow | 41 | 1 | 1 | No | No |
| 17823020 | COMPOSITIONS AND METHODS FOR ENHANCING THE EFFICACY OF CONTRACEPTIVE MICROBICIDES | August 2022 | March 2024 | Allow | 19 | 1 | 0 | No | No |
| 17904833 | A CONTROLLED DRUG RELEASE SYSTEM OF PHOTORESPONSIVE NANOCARRIERS, METHODS OF MAKING AND USING THEREOF | August 2022 | August 2025 | Allow | 35 | 0 | 0 | Yes | No |
| 17878998 | Composition and Method for Transdermal Delivery of Cannabidiol (CBD) and Tetrahydrocannabinol (THC) | August 2022 | August 2025 | Allow | 37 | 2 | 0 | Yes | No |
| 17812479 | Lapatinib particles and uses thereof | July 2022 | January 2024 | Allow | 18 | 2 | 1 | Yes | No |
| 17758308 | GOLD CLUSTERS (AuCs), COMPOSITION AND METHOD FOR TREATMENT OF LIVER CIRRHOSIS | July 2022 | February 2026 | Allow | 43 | 2 | 1 | Yes | No |
| 17787206 | COSMETIC COMPOSITION HAVING GLOSS AND LASTING PROPERTIES | June 2022 | March 2026 | Allow | 45 | 3 | 0 | No | No |
| 17784575 | MINERAL SUPPLEMENTS FOR RUMINANT NUTRITION | June 2022 | March 2025 | Allow | 33 | 2 | 1 | No | No |
| 17756231 | NUTRACEUTICAL OR PHARMACEUTICAL COMPOSITION COMPRISING IRON PYROPHOSPHATE FOR TREATING AND/OR PREVENTING IRON DEFICIENCY CONDITIONS OR DISEASES | May 2022 | January 2026 | Allow | 44 | 2 | 0 | Yes | No |
| 17745923 | Pouches Comprising Oral Care Active Agents | May 2022 | April 2024 | Abandon | 23 | 3 | 0 | No | No |
| 17738803 | THERAPEUTIC COMPOSITIONS FOR TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS | May 2022 | April 2023 | Allow | 11 | 1 | 0 | No | No |
| 17774445 | GASTRIC RESIDENCE SYSTEMS HAVING ARMS WITH CONTROLLED STIFFNESS FOR IMPROVED GASTRIC RESIDENCE | May 2022 | March 2026 | Abandon | 46 | 0 | 1 | No | No |
| 17719912 | ELECTRONIC VAPOR LIQUID COMPOSITION AND METHOD OF USE IN A DISPENSER | April 2022 | September 2024 | Abandon | 29 | 4 | 1 | Yes | No |
| 17713069 | CROSS LINKED SILK-HYALURONIC ACID COMPOSITION | April 2022 | December 2023 | Abandon | 21 | 2 | 0 | No | No |
| 17703955 | COMBINATION OF 25-HYDROXYVITAMIN D AND ANTIOXIDANTS/ANTI-INFLAMMATORIES FOR POULTRY OVARIAN HEALTH | March 2022 | March 2024 | Allow | 24 | 3 | 0 | No | No |
| 17685830 | PHARMACEUTICAL COMPOSITIONS OF PIMOBENDAN | March 2022 | September 2024 | Allow | 31 | 4 | 0 | Yes | No |
| 17680970 | COMPOSITION FOR TREATMENT OF TOPICAL DERMATOLOGICAL BACTERIAL SKIN CONDITIONS | February 2022 | August 2024 | Allow | 29 | 1 | 0 | No | No |
| 17627878 | Porous Self-Healing Polymer Matrix For Encapsulation Of Active Macromolecules And Methods | January 2022 | December 2025 | Allow | 47 | 1 | 1 | Yes | No |
| 17628191 | ANTI-COCCIDIAL PHYTOGENIC FORMULATIONS | January 2022 | May 2025 | Abandon | 40 | 2 | 0 | No | No |
| 17570194 | STABILIZED MODIFIED RELEASE VITAMIN D FORMULATION AND METHOD OF ADMINISTERING SAME | January 2022 | July 2025 | Allow | 43 | 3 | 0 | No | No |
| 17596647 | PROTEIN-MODIFIED PLGA MICROSPHERE AND TISSUE-ENGINEERED NERVE CONSTRUCTED THEREWITH | December 2021 | August 2023 | Allow | 20 | 2 | 0 | Yes | No |
| 17644069 | CENTRAL NERVOUS SYSTEM HEALTH SUPPLEMENT | December 2021 | May 2025 | Allow | 41 | 1 | 0 | No | No |
| 17546640 | EDDS CHELATED NANOCERIA WITH CATALASE-LIKE ACTIVITY | December 2021 | May 2023 | Allow | 17 | 1 | 0 | Yes | No |
| 17540695 | KETAMINE TRANSDERMAL DELIVERY SYSTEM | December 2021 | February 2024 | Abandon | 26 | 1 | 0 | No | No |
| 17595908 | DELAYED DISINTEGRATION-TYPE CAPSULE AND METHOD FOR PRODUCING SAME | November 2021 | September 2025 | Allow | 46 | 2 | 1 | Yes | No |
| 17532874 | BENDAMUSTINE PHARMACEUTICAL COMPOSITIONS | November 2021 | March 2023 | Allow | 15 | 1 | 0 | Yes | No |
| 17612100 | CANNABINOID-COMPRISING COMPOSITIONS FOR MANAGEMENT OF PAIN | November 2021 | May 2025 | Abandon | 42 | 0 | 1 | No | No |
| 17525298 | COMPOSITIONS AND METHODS OF ADMINISTERING BACLOFEN | November 2021 | August 2022 | Allow | 9 | 2 | 0 | No | No |
| 17454320 | IMPLANTABLE DEPOTS FOR THE CONTROLLED RELEASE OF THERAPEUTIC AGENTS | November 2021 | March 2024 | Allow | 28 | 1 | 0 | Yes | No |
| 17609535 | A PHARMACEUTICAL HERBO-MINERAL METALLIC COMPOSITION AND A PROCESS FOR PREPARATION THEREOF | November 2021 | August 2025 | Allow | 46 | 2 | 1 | Yes | No |
| 17595019 | ANTI-CANCER GOLD COMPOUNDS | November 2021 | September 2024 | Allow | 34 | 1 | 0 | No | No |
| 17604615 | GRANULAR PRODUCT BASED ON ARGININE | October 2021 | November 2025 | Allow | 49 | 2 | 0 | No | No |
| 17604133 | NON-AQUEOUS DRIFT CONTROL SUSPENSIONS | October 2021 | July 2025 | Allow | 45 | 2 | 1 | Yes | No |
| 17499648 | METHODS FOR TREATING CHEMORESISTANT CANCER-INITIATING CELLS | October 2021 | April 2024 | Abandon | 30 | 0 | 1 | No | No |
| 17497819 | HIGHLY TRANSPARENT WATER CONTINUOUS DENSE NANOLIPID FLUID (DNLF) DISPERSIONS AND METHOD OF PREPARATION USING A TWIN SCREW EXTRUDER | October 2021 | December 2024 | Allow | 38 | 3 | 1 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner WORSHAM, JESSICA N.
With a 36.8% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 26.1% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner WORSHAM, JESSICA N works in Art Unit 1615 and has examined 701 patent applications in our dataset. With an allowance rate of 55.9%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 30 months.
Examiner WORSHAM, JESSICA N's allowance rate of 55.9% places them in the 17% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by WORSHAM, JESSICA N receive 2.51 office actions before reaching final disposition. This places the examiner in the 73% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by WORSHAM, JESSICA N is 30 months. This places the examiner in the 58% percentile for prosecution speed. Prosecution timelines are slightly faster than average with this examiner.
Conducting an examiner interview provides a +60.6% benefit to allowance rate for applications examined by WORSHAM, JESSICA N. This interview benefit is in the 97% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 16.5% of applications are subsequently allowed. This success rate is in the 13% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 38.4% of cases where such amendments are filed. This entry rate is in the 58% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants request a pre-appeal conference (PAC) with this examiner, 120.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 81% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.
This examiner withdraws rejections or reopens prosecution in 75.9% of appeals filed. This is in the 67% percentile among all examiners. Of these withdrawals, 56.7% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.
When applicants file petitions regarding this examiner's actions, 51.3% are granted (fully or in part). This grant rate is in the 50% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 0.6% of allowed cases (in the 61% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 0% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.